Health policy

Vim Appoints Chief Revenue Officer to Support New Phase of Growth

Retrieved on: 
Thursday, January 2, 2020
Health, Hospitals, Practice Management, Other Health, Managed care, General Health, Biotechnology, Publicly funded health care, Cleaning products, Castlight Health, Vim, Health policy

Leonards appointment comes on the heels of the companys $24M Series B financing and significant growth in customer and business operations.

Key Points: 
  • Leonards appointment comes on the heels of the companys $24M Series B financing and significant growth in customer and business operations.
  • Mike joining our team is a real validation of the value Vim delivers to our members, payer customers, and provider partners, said Oron Afek, CEO and Co-founder of Vim.
  • Before joining Vim, Leonard was Chief Commercial Officer at Castlight Health leading all go-to-market teams for Castlights health navigation platform.
  • Vim partners with health plans and care providers to deploy a digital network operating system for value-based care.

Global Cold Pain Therapy Market Analysis, Trends, and Forecasts, 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 31, 2019
Health, Pharmaceutical, Health, Articles, Drug discovery, Health policy, Medicinal chemistry, Therapy

The "Cold Pain Therapy - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cold Pain Therapy - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Cold Pain Therapy market worldwide is projected to grow by US$657.3 Million, driven by a compounded growth of 4.7%.
  • OTC Products, one of the segments analyzed and sized in this study, displays the potential to grow at over 5.1%.
  • Poised to reach over US$1.8 Billion by the year 2025, OTC Products will bring in healthy gains adding significant momentum to global growth.

Public Health Nursing: Population-Centered Health Care in the Community, 10th Edition - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 19, 2019
Nursing, Health, Health, Articles, Health Economics, Health policy, Primary care, Euthenics, Public health, Health care, Nursing, Bachelor of Science in Nursing, Marie Manthey

Public Health Nursing: Population-Centered Health Care in the Community, 10th Edition provides up-to-date information on issues such as infectious diseases, natural and man-made disasters, and healthcare policies affecting individuals, families, and communities.

Key Points: 
  • Public Health Nursing: Population-Centered Health Care in the Community, 10th Edition provides up-to-date information on issues such as infectious diseases, natural and man-made disasters, and healthcare policies affecting individuals, families, and communities.
  • Ideal for BSN and Advanced Practice Nursing programs, this comprehensive, bestselling text will provide you with a greater understanding of public health nursing!
  • History of Public Health and Public and Community Health Nursing 3.
  • Economics of Health Care Delivery
    Part 2: Forces Affecting Nurses in the Delivery of Public and Population Health Care Delivery 6.

Patient Engagement Technology: an Innovative Tool for Healthcare Industry (2019 Report) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 18, 2019
Technology, General Health, Health, Other Technology, Healthcare quality, Health Economics, Health care, Health policy, Patient participation, Draft:Primary Care Occupational Therapy Annotated Bibliography

The "Patient Engagement Technology an Innovative Tool for Healthcare Industry, End User Market Trends and Analysis - (Price Analysis, Replacement Trends and Factor Analysis, Selection Criteria, Buying Behavior and Mobile health)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Patient Engagement Technology an Innovative Tool for Healthcare Industry, End User Market Trends and Analysis - (Price Analysis, Replacement Trends and Factor Analysis, Selection Criteria, Buying Behavior and Mobile health)" report has been added to ResearchAndMarkets.com's offering.
  • The patient engagement solutions market is expected to grow rapidly as the healthcare industry is witnessing a shift to a value-based reimbursement system from the traditional volume-based fee-for-reimbursement system.
  • Patient engagement solutions offer benefits such as cost reduction, reduced readmission rates, enhanced staff productivity, and management of patients across the care continuum.
  • Patient engagement solutions are deployed in many organizations across the globe.

Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, December 17, 2019
Articles, Health, Drug discovery, Health policy, Medicinal chemistry, Therapy, Life sciences

Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.

Key Points: 
  • Turning Point Therapeuticsis a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • These forward-looking statements are based upon Turning Point Therapeutics current expectations and involve assumptions that may never materialize or may prove to be incorrect.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Anixa Biosciences Provides Update on CAR-T Program

Retrieved on: 
Friday, December 13, 2019
Health sciences, Health, Articles, Drug discovery, Health policy, Medicinal chemistry, Therapy, Gurgaon kidney scandal

Dr. Amit Kumar, President and CEO of Anixa Biosciences stated, "While this new development may be disappointing to shareholders, we have decided that we want to go into the clinic with the best possible therapy.

Key Points: 
  • Dr. Amit Kumar, President and CEO of Anixa Biosciences stated, "While this new development may be disappointing to shareholders, we have decided that we want to go into the clinic with the best possible therapy.
  • The Anixa and Moffitt teams will strive to get into the clinic as soon as possible with the best possible therapy," commented Dr. Conejo-Garcia.
  • Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer.
  • You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.

Good Clean Love Launches First-of-Its-Kind Medical Research Resource for Women's Health

Retrieved on: 
Thursday, December 12, 2019
Articles, Health, Health Economics, Public health, Health policy, Euthenics, Vagina, Health education, Health professional

EUGENE, Ore., Dec. 12, 2019 /PRNewswire/ -- Good Clean Love , the renowned natural personal care products company, has launched a first-of-its-kind resource for Women's Health.

Key Points: 
  • EUGENE, Ore., Dec. 12, 2019 /PRNewswire/ -- Good Clean Love , the renowned natural personal care products company, has launched a first-of-its-kind resource for Women's Health.
  • "There is a gap in vaginal health education access to research and resources compared to other reproductive specific health research.
  • "It is challenging for both Medical professionals and consumers alike to know what is actually safe," explained Wendy Strgar, founder of Good Clean Love.
  • Good Clean Love has donated more than one million sample products through partnerships with thousands of medical practitioners.

Hospital Budgets 2020: Resist the Cost-Cut Bias and Invest for Success - Industry Analysis by Loyale Healthcare

Retrieved on: 
Wednesday, December 11, 2019
Health policy, Publicly funded health care, HCA Healthcare

Healthcare Policy - "Dealing with current healthcare policy regulation, political uncertainty/antagonism"

Key Points: 
  • Healthcare Policy - "Dealing with current healthcare policy regulation, political uncertainty/antagonism"
    Based on the conclusions of this and a variety of other industry organizations and analysts, it's clear that patients - the consumers of healthcare - are the dominant consideration for healthcare in 2020.
  • Loyale Healthcare is committed to a mission of turning patient responsibility into lasting loyalty for its healthcare provider customers.
  • Based in Lafayette, California, Loyale and its leadership team bring 27 years of expertise delivering leading financial engagement solutions for complex business environments.
  • Loyale recently announced an Enterprise level strategic partnership with Parallon including deployment of its industry leading technology to all HCA hospitals and Physician Groups.

New Report Calls for Measurement of Outcomes and Federal Funding for Research and Increased Capacity at FDA to Advance Safe and Effective Regenerative Cell Therapies

Retrieved on: 
Tuesday, December 10, 2019
Health sciences, Articles, Health, Drug discovery, Health policy, Medicinal chemistry, Therapy, Stem cells

Regenerative cell therapies represent the next generation of treatments that are showing great promise in cardiology, neurology, oncology, orthopedics, osteoarthritis, and wound healing.

Key Points: 
  • Regenerative cell therapies represent the next generation of treatments that are showing great promise in cardiology, neurology, oncology, orthopedics, osteoarthritis, and wound healing.
  • Increasing and sustaining funding for regenerative cell therapy research and clinical trials at the NIH to advance the science and the field, which was noted by several private sector panelists.
  • Gaining consensus on and driving adoption of standards and best practices to support the development, manufacturing, and delivery of regenerative cell therapies.
  • To read the entire report, go to http://allianceforcelltherapynow.org/wp-content/uploads/2019/12/Regenera...
    To view speaker slides and a webcast of the event, visit http://allianceforcelltherapynow.org/events/ .

Making Cell and Gene Therapies Financially Accessible and Sustainable

Retrieved on: 
Monday, December 9, 2019
Health sciences, Health, Articles, Health policy, Patient advocacy, Therapy

The free online resource helps payers, patient advocates, drug developers, policymakers, and other healthcare system stakeholders explore strategies to sustainably finance new cell and gene therapies with durableand potentially curativeeffects.

Key Points: 
  • The free online resource helps payers, patient advocates, drug developers, policymakers, and other healthcare system stakeholders explore strategies to sustainably finance new cell and gene therapies with durableand potentially curativeeffects.
  • Yet, these therapies pose significant financing challenges for many consumers and payers.
  • The Toolkit also empowers patient advocacy organizations, eager to make new therapies accessible to their communities.
  • "Helping implement, not just envision, precision financing solutions for durable cell and gene therapies is a critical part of the FoCUS mission," said Mark Trusheim, Strategic Director, NEWDIGS.